FibroBiologics Statistics
Total Valuation
FibroBiologics has a market cap or net worth of $120.59 million. The enterprise value is $133.02 million.
| Market Cap | 120.59M |
| Enterprise Value | 133.02M |
Important Dates
The next estimated earnings date is Saturday, November 2, 2024, before market open.
| Earnings Date | Nov 2, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
FibroBiologics has 35.26 million shares outstanding. The number of shares has increased by 6.55% in one year.
| Shares Outstanding | 35.26M |
| Shares Change (YoY) | +6.55% |
| Shares Change (QoQ) | +5.09% |
| Owned by Insiders (%) | 22.17% |
| Owned by Institutions (%) | 9.53% |
| Float | 25.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.64
| Current Ratio | 0.64 |
| Quick Ratio | 0.59 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,120.50 |
Financial Efficiency
Return on equity (ROE) is -434.33% and return on invested capital (ROIC) is -110.33%.
| Return on Equity (ROE) | -434.33% |
| Return on Assets (ROA) | -61.55% |
| Return on Capital (ROIC) | -110.33% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.95M |
| Employee Count | 10 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 3.36 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 60.80 |
| Average Volume (20 Days) | 751,655 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.21M |
| Pretax Income | -19.47M |
| Net Income | -19.47M |
| EBITDA | -11.09M |
| EBIT | -11.21M |
| Earnings Per Share (EPS) | -$0.65 |
Balance Sheet
The company has $5.97 million in cash and $1.84 million in debt, giving a net cash position of $4.14 million or $0.12 per share.
| Cash & Cash Equivalents | 5.97M |
| Total Debt | 1.84M |
| Net Cash | 4.14M |
| Net Cash Per Share | $0.12 |
| Equity (Book Value) | -2.39M |
| Book Value Per Share | -0.07 |
| Working Capital | -3.62M |
Cash Flow
In the last 12 months, operating cash flow was -$8.96 million and capital expenditures -$489,000, giving a free cash flow of -$9.45 million.
| Operating Cash Flow | -8.96M |
| Capital Expenditures | -489,000 |
| Free Cash Flow | -9.45M |
| FCF Per Share | -$0.27 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FibroBiologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.55% |
| Shareholder Yield | -6.55% |
| Earnings Yield | -14.20% |
| FCF Yield | -6.89% |
Analyst Forecast
The average price target for FibroBiologics is $16.00, which is 367.84% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.00 |
| Price Target Difference | 367.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |